Collectively, blocking Hsp90 ATPase activity by using specific inhibitors can be an attractive strategy for overcoming the limitations of conventional GBM treatment, as many Hsp90 client proteins are involved in the GBM development and maintenance, including CyclinD1, CDK4, Akt, and EGFR. Here, CCND1 is linked to glioblastoma.